Regeneron Pharmaceuticals, Inc. If approved, Dupixent would be the first and only targeted medicine in the EU for these young children Recommendation based on a Phase 3 trial in children 6 months to 5 years old ...
Dupixent is the first and only biologic that significantly improved skin clearance, and reduced itch and overall disease severity in children as young as 6 months old in a Phase 3 trial Published results ...
Late-breaking Dupixent® (dupilumab)data at ERS 2022 show consistent efficacy and safetyprofile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma Results from the longest global Phase 3 open-label extension ...
TARRYTOWN, N.Y. and PARIS, June 7, 2022 Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, experienced significantly improved overall disease severity and significantly reduced itch compared to TCS alone at week 16 ...
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis • Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis ...
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from ...
FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis If approved, Dupixent will be the first biologic medicine available in the U.S. to treat uncontrolled ...
Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session Dupixent significantly improved skin clearance and reduced overall disease severity and itch ...
TARRYTOWN, N.Y. and PARIS, Dec. 13, 2021 /PRNewswire/ — Dupixent significantly improved skin clearance and reduced overall disease severity and itch in pivotal trial that met all primary and secondary endpoints Global regulatory filings planned ...
